Journal ArticleOPEN ACCESS

A Case of Nivolumab-Induced Myositis

  • Fox E
  • Dabrow M
  • Ochsner G
The Oncologist (2016) 21(12) e3-e3
DOI: 10.1634/theoncologist.2016-0170
27Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Nivolumab (Opdivo) is a monoclonal antibody classified as an immune modulator. A case is presented of nivolumab-induced myositis, an unlisted side effect.

Cite

CITATION STYLE

APA

Fox, E., Dabrow, M., & Ochsner, G. (2016). A Case of Nivolumab-Induced Myositis. The Oncologist, 21(12), e3–e3. https://doi.org/10.1634/theoncologist.2016-0170

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free